These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 25884701)

  • 1. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
    Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
    J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
    Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
    Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
    Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
    BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
    Tonin PN; Mes-Masson AM; Narod SA; Ghadirian P; Provencher D
    Clin Genet; 1999 May; 55(5):318-24. PubMed ID: 10422801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
    Tonin PN; Mes-Masson AM; Futreal PA; Morgan K; Mahon M; Foulkes WD; Cole DE; Provencher D; Ghadirian P; Narod SA
    Am J Hum Genet; 1998 Nov; 63(5):1341-51. PubMed ID: 9792861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
    J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
    Cote S; Arcand SL; Royer R; Nolet S; Mes-Masson AM; Ghadirian P; Foulkes WD; Tischkowitz M; Narod SA; Provencher D; Tonin PN
    Breast Cancer Res Treat; 2012 Jan; 131(1):333-40. PubMed ID: 21947752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
    Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
    Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
    Ancot F; Arcand SL; Mes-Masson AM; Provencher DM; Tonin PN
    Oncol Lett; 2015 Jun; 9(6):2787-2790. PubMed ID: 26137147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
    Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
    BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
    Sakamoto I; Hirotsu Y; Nakagomi H; Ouchi H; Ikegami A; Teramoto K; Amemiya K; Mochizuki H; Omata M
    Cancer; 2016 Jan; 122(1):84-90. PubMed ID: 26439132
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.